Exemestane vs. Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer

This is an ongoing, multi-center randomized clinical trial for breast cancer prevention in high risk postmenopausal women.

Title: A Phase III Randomized Study of Exemestance Plus Placebo vs. Exemestane Plus Celecoxib vs. Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer (referred to as ExCel study).

Principal Investigator: Jean Wactawski-Wende, PhD

Funding Agency: National Cancer Institute of Canada

Period: 09/17/04 - 09/15/17

Abstract: This is an ongoing, multi-center randomized clinical trial for breast cancer prevention in high risk postmenopausal women. The study participants were randomized either to the aromatase inhibitor exemestane or placebo.